Opportunities are available for individuals with Multiple Sclerosis to participate in several new clinical trials at the University of Maryland Center for Multiple Sclerosis.  These studies are either currently enrolling or will be enrolling shortly. The studies vary in design, duration, criteria for eligibility, number of MRI scans, and other details. The following is a very brief summary of each study. You may obtain further information by calling Kerry Naunton, R.N., 410-328-5605 at the MS Center.

  1. High field MRI for visualization of cortical pathology, meningeal inflammation, and neurodegeneration in multiple sclerosis

    Application No:
    HP-00064127
    Principal Investigator: Daniel Harrison

    This research is investigating the use of high-field (7-tesla) MRI in visualizing MS-related damage to the gray matter of the brain, degeneration of nerves and inflammation in the protective tissues around the brain.

    Volunteers should be 18-65 years old and have multiple sclerosis. A cohort of healthy volunteers (without MS), ages 18-65, are also invited to participate.

    Participants will undergo an MRI of the brain, an OCT scan, and disability and cognitive testing.
  2. Clinical Biomarkers of Disease Activity and Treatment Response in Patients with CNS Sarcoidosis Treated with H.P. Acthar® Gel

    Patients are needed for an investigator-sponsored study on the use of Acthar Gel in patients with neurosarcoidosis. Study drug will be provided by Mallinckrodt Pharmaceuticals.

    The purpose of this study is to find whether the drug Acthar can reduce chronic inflammation and improve quality of life in patients with CNS sarcoidosis. Another way of treating CNS sarcoidosis is to use a hormone called adrenocorticotropic hormone, or ACTH.

    ACTH is available for patient use as the drug Acthar. In this study we will find whether treatment with Acthar can improve of a person’s CNS sarcoidosis and whether being on such treatment can help a person lead a more pleasant and productive life. We will also test samples of blood and spinal fluid to see how Acthar affects immune system function.

    Eligibility:
    • A highly probable diagnosis of sarcoidosis with involvement not limited to the central nervous system.
    • At the time of enrollment, a history of clinical deterioration based on the development of new symptoms or worsening previously present symptoms with confirmation by clinical examination and objective clinical testing.
    • If on steroids, on a stable dose of the medication for at least 3 months.
  3. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To Evaluate The Safety And Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

    Learn more about this trial here.
  4. An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (MN30035)

    Learn more about this trial here.
  5. A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis COMB157G2302

    Learn more about this trial here.

Currently recruiting clinical trial opportunities are constantly changing. Please keep in touch if you are interested in trials!